|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
68,990,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Bicycle Therapeutics is a holding company. Through its subsidiaries, Co. is a clinical-stage biopharmaceutical company developing a class of medicines, which it refers to as Bicycles. Bicycles are a therapeutic modality combining the pharmacology associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Co. is evaluating BT5528, a Bicycle Toxin Conjugate (BTC) targeting Ephrin type-A receptor 2, BT8009, a BTC targeting Nectin-4, and BT7480, a Bicycle tumor-targeted immune cell agonist® targeting Nectin-4 and agonizing CD137. In addition, BT1718, a BTC that is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
7,268 |
14,490 |
37,488 |
61,094 |
Total Sell Value |
$142,744 |
$314,362 |
$724,634 |
$1,369,761 |
Total People Sold |
7 |
7 |
7 |
9 |
Total Sell Transactions |
7 |
14 |
26 |
45 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Keen Nicholas |
Chief Scientific Officer |
|
2021-09-16 |
4 |
AS |
$45.01 |
$87,995 |
D/D |
(1,955) |
3,366 |
|
- |
|
Keen Nicholas |
Chief Scientific Officer |
|
2021-09-15 |
4 |
AS |
$45.00 |
$135,000 |
D/D |
(3,000) |
5,321 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2021-09-02 |
4 |
AS |
$40.00 |
$400,000 |
D/D |
(10,000) |
0 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2021-09-02 |
4 |
OE |
$9.82 |
$98,200 |
D/D |
10,000 |
10,000 |
|
- |
|
Keen Nicholas |
Chief Scientific Officer |
|
2021-09-02 |
4 |
AS |
$40.00 |
$400,000 |
D/D |
(10,000) |
8,321 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-09-02 |
4 |
AS |
$40.00 |
$200,000 |
D/D |
(5,000) |
235,085 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-09-01 |
4 |
AS |
$36.38 |
$1,007,897 |
D/D |
(27,085) |
240,085 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-09-01 |
4 |
OE |
$14.00 |
$320,460 |
D/D |
22,890 |
267,170 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-08-31 |
4 |
AS |
$36.23 |
$407,763 |
D/D |
(11,225) |
244,280 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-08-31 |
4 |
OE |
$14.00 |
$145,880 |
D/D |
10,420 |
255,505 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-08-27 |
4 |
AS |
$36.02 |
$65,124 |
D/D |
(1,808) |
245,085 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-08-27 |
4 |
OE |
$14.00 |
$25,312 |
D/D |
1,808 |
246,893 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2021-08-27 |
4 |
AS |
$35.15 |
$279,443 |
D/D |
(7,950) |
0 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2021-08-27 |
4 |
OE |
$8.73 |
$69,404 |
D/D |
7,950 |
7,950 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2021-08-26 |
4 |
AS |
$35.04 |
$19,272 |
D/D |
(550) |
0 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2021-08-26 |
4 |
OE |
$8.76 |
$4,818 |
D/D |
550 |
550 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2021-08-23 |
4 |
AS |
$33.02 |
$247,650 |
D/D |
(7,500) |
0 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2021-08-23 |
4 |
OE |
$1.60 |
$12,000 |
D/D |
7,500 |
7,500 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2021-07-29 |
4 |
AS |
$31.24 |
$393,823 |
D/D |
(12,500) |
0 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2021-07-29 |
4 |
OE |
$1.63 |
$20,375 |
D/D |
12,500 |
12,500 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-07-26 |
4 |
AS |
$36.00 |
$3,600 |
D/D |
(100) |
245,085 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-07-26 |
4 |
OE |
$14.00 |
$1,400 |
D/D |
100 |
245,185 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-07-23 |
4 |
AS |
$36.02 |
$172,248 |
D/D |
(4,782) |
245,085 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-07-23 |
4 |
OE |
$14.00 |
$66,948 |
D/D |
4,782 |
249,867 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-07-16 |
4 |
AS |
$34.00 |
$20,706 |
D/D |
(609) |
245,085 |
|
- |
|
226 Records found
|
|
Page 5 of 10 |
|
|